Wednesday July 18, 2018 0 comments
BOULDER -- SomaLogic and Massachusetts-based GNS Healthcare announced SomaLogic has obtained a license to apply GNS Healthcare's proprietary REFS (Reverse Engineering & Forward Simulation) causal machine-learning technology to SomaLogic's proprietary SOMAscan-derived protein data sets.
The goal of the agreement is to leverage REFS to rapidly accelerate the translation of SomaLogic's massive protein data into meaningful and actionable information for individual and population health management, SomaLogic said.
Living organisms function through complicated interconnected biological networks that respond dynamically to factors such as diet, environment, medication, infection and disease.
SomaLogic's SOMAscan platform taps into these networks by repeatedly measuring the changing levels of thousands of proteins circulating through the body over time.
These large data sets require increasingly powerful machine learning-based tools like GNS Healthcare's unique REFS platform, which builds computational models of the biological networks from the raw data to reveal new understandings of disease and even potential interventions.
"Our ability to measure 5,000 proteins in each of hundreds of thousands of samples requires that we be able to analyze all those data in a way that will ultimately result in making a difference for individuals and their health providers," said Alister Reynolds, SomaLogic CEO.
"We believe that GNS Healthcare's powerful REFS technology has the potential to become a critical tool for extracting those meaningful health insights."
"Our REFS platform has proven itself repeatedly with genomic, transcriptomic, metabolite, clinical, labs, EMR, claims, and other data types, and we are excited to see how well it performs on real-time biological measurements like proteins," said Colin Hill, GNS Healthcare CEO and co-founder.
"SOMAscan-derived protein data are perfectly suited to the REFS workflow, and we look forward to our platform fully proving its value again in this setting."
Further specifics about the agreement were not disclosed.